Ketorolac
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Ketorolac: From Acute Pain to Headache Disorder
One-Sentence Summary
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) originally used for short-term management of moderate to severe acute pain (e.g., postoperative pain). The TxGNN model predicts it may be effective for Headache Disorder (primarily migraine and tension-type headache), with 37 clinical trials and 19 publications currently supporting this direction — though the drug is not currently marketed in Germany.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute pain management (NSAID; short-term treatment of moderately severe pain) |
| Predicted New Indication | Headache Disorder (migraine / tension-type headache) |
| TxGNN Prediction Score | 99.43% |
| Evidence Level | L1 |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack (data gap DG002). Based on known information, ketorolac is a pyrrolizine-carboxylic-acid class NSAID that acts through non-selective inhibition of COX-1/COX-2, reducing prostaglandin synthesis. Its efficacy in acute pain has been well established for decades, and mechanistically this same anti-prostaglandin action may extend to headache disorders, since prostaglandin-mediated neurogenic inflammation and trigeminovascular activation are recognized contributors to migraine and tension-type headache pain.
Acute pain and headache disorder are pharmacologically related: both involve peripheral and central sensitization driven partly by prostaglandins, and NSAIDs are already a first-line class for both. This mechanistic overlap is likely why the TxGNN model connects ketorolac's original acute-pain profile to headache disorder with a very high score.
Real-world clinical practice already supports this link — parenteral ketorolac (IV/IM/intranasal) has been used off-label as a standard emergency-department treatment for acute migraine and tension-type headache for over 30 years, and is explicitly included as a comparator/standard therapy in the 2025 American Headache Society guideline update for parenteral migraine treatment in the ED. In this sense, the TxGNN prediction largely formalizes an already-established off-label clinical pattern rather than proposing a novel mechanism.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01267864 | Phase 4 | Completed | 330 | IV valproate vs metoclopramide vs ketorolac for acute migraine |
| NCT01807234 | Phase 4 | Completed | 72 | Ketorolac nasal spray vs sumatriptan nasal spray vs placebo for acute migraine, including nausea/allodynia outcomes |
| NCT02358681 | Phase 3 | Completed | 59 | Intranasal vs IV ketorolac non-inferiority trial for pediatric migraine |
| NCT03081416 | Phase 3 | Completed | 80 | THINK Trial: intranasal ketamine vs standard therapy (ketorolac) for ED headache |
| NCT01011673 | Phase 4 | Completed | 123 | Metoclopramide/diphenhydramine vs ketorolac alone for tension-type headache |
| NCT01596166 | Phase 4 | Completed | 56 | IV ketorolac + metoclopramide combination for pediatric migraine in ED |
| NCT00483717 | Phase 2 | Completed | 173 | Randomized, placebo-controlled trial of intranasal ketorolac for acute migraine |
| NCT01138150 | Phase 4 | Completed | 36 | Inflammatory marker changes during acute migraine attacks treated with ketorolac |
| NCT06083571 | Phase 2 | Terminated | 41 | Intranasal ketorolac + oral adjuncts vs IV ketorolac for pediatric migraine |
| NCT02664116 | Phase 4 | Unknown | 40 | IM ketorolac vs oral diclofenac potassium for severe migraine |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9484382 | 1998 | RCT | Neurology | IM ketorolac 60mg significantly more effective than meperidine+promethazine or saline for tension-type headache over 6 hours |
| 1514724 | 1992 | RCT | Annals of Emergency Medicine | IM ketorolac compared with meperidine+hydroxyzine for acute migraine |
| 35670115 | 2022 | RCT | Headache | Adding IV ketorolac to metoclopramide for pediatric migraine in the ED |
| 30783794 | 2019 | RCT | Neurological Sciences | Compared dexamethasone, metoclopramide, ketorolac, and chlorpromazine for migraine pain relief and recurrence prevention |
| 41321235 | 2026 | Guideline | Headache | 2025 AHS guideline update on parenteral migraine pharmacotherapy in the ED |
| 25600718 | 2015 | Guideline/Review | Headache | AHS evidence assessment of migraine pharmacotherapies |
| 39674934 | 2025 | Systematic Review/Meta-analysis | Annals of Emergency Medicine | Bayesian network meta-analysis of ED pharmacologic therapies for migraine |
| 35138658 | 2022 | Systematic Review/Meta-analysis | Academic Emergency Medicine | Efficacy of parenteral ketorolac for acute migraine attack |
| 37849443 | 2024 | Systematic Review/Meta-analysis | Adv Clin Exp Med | IV ketorolac vs metoclopramide for adult migraine headaches |
| 8240554 | 1993 | Observational (Patient-evaluated) | American Journal of Emergency Medicine | Ketorolac reduced migraine pain/nausea rapidly per patient self-assessment at 30/60/90 min |
Safety Considerations
Please refer to the package insert for safety information. No TFDA warnings, contraindications, or drug-interaction data could be extracted for this evidence pack (data gap DG001, flagged Blocking — this must be resolved before any S1 safety pre-screening can proceed).
Conclusion and Next Steps
Decision: Hold
Rationale: Efficacy evidence is unusually strong for a repurposing candidate — dozens of completed Phase 2–4 RCTs, multiple systematic reviews/meta-analyses, and inclusion in the 2025 American Headache Society ED migraine guideline (Evidence Level L1). However, the drug currently has zero market authorizations in Germany, and safety labeling data (warnings, contraindications, DDI) is completely unavailable — a Blocking data gap that prevents entry into the S1 safety pre-screening stage regardless of efficacy strength.
To proceed, the following is needed:
- TFDA/manufacturer package insert with full warnings, contraindications, and precautions (resolve DG001)
- Detailed mechanism of action / pharmacology profile from DrugBank or primary literature (resolve DG002)
- Confirmation of feasible administration route (IV/IM/intranasal) aligned with ED migraine treatment protocols
- Assessment of regulatory pathway given the drug's current unmarketed status in Germany
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.